Ocular surface squamous neoplasia (OSSN) is the most common malignancy of the ocular surface, often presenting as a non-pigmented lesion with atypical squamous epithelialization. It is usually asymptomatic and can be confused with benign conditions such as pterygium or conjunctival cysts. If untreated, OSSN may progress to invasive squamous cell carcinoma, causing vision loss or metastasis. The gold standard for diagnosing OSSN is histopathological examination after tumor resection. However, there are still unresolved issues in the clinical management of treatment.
Main text
In this review, we have discussed the clinical characteristics, diagnostic techniques, and treatment options for OSSN. OSSN occurs due to changes in the living environment and ocular surface state. It starts as a benign squamous epithelial tumor, which can progress to atypical intraepithelial neoplasia and eventually turn into invasive squamous cell carcinoma. The postoperative pathological histology also shows a corresponding degree of differentiation. Various diagnostic techniques, such as diagnostic imaging, cell biology, and molecular biology, are emerging as valuable tools for distinguishing OSSN. Although surgical resection is the primary treatment for OSSN, drug therapy can also be applied for better management of OSSN treatment.
Conclusion
Accurately diagnosing OSSN requires advanced examination techniques before and after operation. This is crucial for healthcare professionals to evaluate and treat the condition effectively. Based on our clinical expertise, administering drug treatment before or after surgical resection may serve as a comprehensive and effective management approach for OSSN. This research holds immense potential for the future of personalized and precise medical care.
GichuhiSSagooMSWeissHA,et al.Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health2013; 18: 1424–1443.
4.
ZoroquiainPJabbourSAldreesS, et al.High frequency of squamous intraepithelial neoplasia in pterygium related to low ultraviolet light exposure. Saudi J Ophthalmol2016; 30: 113–116.
5.
GichuhiSMachariaEKabiruJ, et al.Risk factors for ocular surface squamous neoplasia in Kenya: a case-control study. Trop Med Int Health2016; 21: 1522–1530.
6.
FasinaO. Ocular surface squamous neoplasia at a tertiary eye facility, Southwestern Nigeria: a 10-year review. Int Ophthalmol2021; 41: 3325–3331.
7.
TananuvatNNiparugsMWiwatwongwanaD, et al.Ocular surface squamous neoplasia in Northern Thailand: a 16-year review. BMC Ophthalmol2022; 22: 121.
8.
ShieldsCLShieldsJA. Tumors of the conjunctiva and cornea. Indian J Ophthalmol2019; 67: 1930–1948.
9.
ReeseAMargoCE. Conjunctival squamous intraepithelial neoplasia and its differential diagnosis. J Clin Pathol2022; 75: 354–358.
10.
MaIHHuFRWangIJ, et al.Clinicopathologic correlation of ocular surface squamous neoplasia from a university hospital in North Taiwan 1994 to 2014. J Formos Med Assoc2019; 118: 776–782.
11.
YousefYAFingerPT. Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases. Ophthalmology2012; 119: 233–240.
12.
ShieldsCLAlsetAEBoalNS, et al.Conjunctival tumors in 5002 cases. Comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen Lecture. Am J Ophthalmol2017; 173: 106–133.
13.
KimBHKimMKWeeWR,et al.Clinical and pathological characteristics of ocular surface squamous neoplasia in an Asian population. Graefes Arch Clin Exp Ophthalmol2013; 251: 2569–2573.
14.
MittalRRathSVemugantiGK. Ocular surface squamous neoplasia - review of etio-pathogenesis and an update on clinico-pathological diagnosis. Saudi J Ophthalmol2013; 27: 177–186.
15.
Yin VT, Merritt HA, Sniegowski M, et al. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol, 2015; 33: 159–169.
16.
HӧllhumerRMichelowPWilliamsS. Demographics, clinical presentation and risk factors of ocular surface squamous neoplasia at a tertiary hospital, South Africa. Eye (Lond)2023; 37: 3602–3608.
HabibalahiAAllendeAMichaelJ, et al.Pterygium and ocular surface squamous neoplasia: Optical biopsy using a novel autofluorescence multispectral imaging technique. Cancers (Basel)2022; 14: 1591.
19.
KheirWJTetzlaffMTPfeifferML, et al.Epithelial, non-melanocytic and melanocytic proliferations of the ocular surface. Semin Diagn Pathol2016; 33: 122–132.
20.
CarrilhoCMiuCKimY, et al.P16 expression correlates with invasive ocular surface squamous neoplasms in HIV-infected Mozambicans. Ocul Oncol Pathol2020; 6: 123–128.
21.
TeránSAhumadaFVergaraF, et al.OVOL1 Immunohistochemical expression is a useful tool to diagnose invasion in ocular surface squamous neoplasms. Arch Soc Esp Oftalmol (Engl Ed)2022; 97: 504–509.
22.
AgarwalAKalikiSMurthySI. Corneal squamous neoplasia: masquerades and management outcomes at a rural eyecare centre. BMJ Case Rep2023; 16: e254365.
23.
SinghSMittalRNarangP,et al.Corneal epithelial hyperplasia masquerading as ocular surface squamous neoplasia. Indian J Ophthalmol2020; 68: 2491–2492.
24.
MoshirfarMKhalifaYMKuoA, et al.Ocular surface squamous neoplasia masquerading as superior limbic keratoconjunctivitis. Middle East Afr J Ophthalmol2011; 18: 74–76.
PelosiniLSmithHBSchofieldJB, et al.In vivo optical coherence tomography (OCT) in periocular basal cell carcinoma: correlations between in vivo OCT images and postoperative histology. Br J Ophthalmol2013; 97: 890–894.
27.
VempuluruVSJakatiSGodboleA, et al.Spectrum of AS-OCT features of ocular surface tumors and correlation of clinico-tomographic features with histopathology: a study of 70 lesions. Int Ophthalmol2021; 41: 3571–3586.
28.
BaşkanCKılıcarslanA. How can we diagnose ocular surface squamous neoplasia with optical coherence tomography?Cureus2023; 15: e36320.
29.
FüstÁTóthJImreL,et al.Non-malignant conjunctival epithelial masses with ocular surface squamous neoplasia-like optical coherence tomography features. Int Ophthalmol2021; 41: 1827–1834.
30.
SinghSMittalRGhoshA, et al.High-Resolution anterior segment optical coherence tomography in intraepithelial versus invasive ocular surface squamous neoplasia. Cornea2018; 37: 1292–1298.
31.
SunYHuaR. Ocular surface squamous neoplasia: angiographic characteristics and response to subconjunctival/perilesional 5-fluorouracil injections. Drug Des Devel Ther2019; 13: 1323–1334.
32.
ThomasBJGalorANanjiAA, et al.Ultra high-resolution anterior segment optical coherence tomography in the diagnosis and management of ocular surface squamous neoplasia. Ocul Surf2014; 12: 46–58.
33.
KievalJZKarpCLShoushaA, et al.Ultra-high resolution optical coherence tomography for differentiation of ocular surface squamous neoplasia and pterygia. Ophthalmology2012; 119: 481–486.
34.
AtallahMJoagMGalorA, et al.Role of high resolution optical coherence tomography in diagnosing ocular surface squamous neoplasia with coexisting ocular surface diseases. Ocul Surf2017; 15: 688–695.
35.
XuYZhouZXuY, et al.The clinical value of in vivo confocal microscopy for diagnosis of ocular surface squamous neoplasia. Eye (Lond)2012; 26: 781–787.
36.
AlomarTSNubileMLoweJ,et al.Corneal intraepithelial neoplasia: in vivo confocal microscopic study with histopathologic correlation. Am J Ophthalmol2011; 151: 238–247.
37.
IovienoALongoCDe LucaM, et al.Fluorescence confocal microscopy for ex vivo diagnosis of conjunctival tumors: a pilot study. Am J Ophthalmol2016; 168: 207–216.
38.
ToleDMMcKelviePADaniellM. Reliability of impression cytology for the diagnosis of ocular surface squamous neoplasia employing the Biopore membrane. Br J Ophthalmol2001; 85: 154–158.
39.
SawadaYFischerJLVermAM, et al.Detection by impression cytologic analysis of conjunctival intraepithelial invasion from eyelid sebaceous cell carcinoma. Ophthalmology2003; 110: 2045–2050.
40.
Barros JdeNAlmeidaSRLowenMS, et al.Impression cytology in the evaluation of ocular surface tumors: review article. Arq Bras Oftalmol2015; 78: 126–132.
41.
KayatKVCorrea DantasPEFelbergS, et al.Exfoliative cytology in the diagnosis of ocular surface squamous neoplasms. Cornea2017; 36: 127–130.
42.
SemenovaEAMilmanTFingerPT, et al.The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia. Am J Ophthalmol2009; 148: 772–8.e1.
43.
MoshtaghionSMAbolhosseiniMRezaei KanaviM, et al.Impression cytology for detection of clinically suspected ocular surface disorders: a cross-sectional study. Eur J Ophthalmol2021; 31: 943–950.
44.
DesjardinsL. Looking deeper into the tumour cell genome for a better diagnosis, a better understanding of cell biology, a better prognostication and finally a better treatment. Br J Ophthalmol2013; 97: 802.
45.
ChauhanSSenSChauhanSS, et al.Stratifin in ocular surface squamous neoplasia and its association with p53. Acta Ophthalmol2021; 99: e1483–e1e91.
46.
GurnaniBKaurK. Molecular and epigenetic mechanisms governing ocular surface squamous neoplasia: opportunities for diagnostics. Expert Rev Mol Diagn2023; 12: 1–15.
47.
BonevaSSchlechtAZhangP, et al.MACE RNA sequencing analysis of conjunctival squamous cell carcinoma and papilloma using formalin-fixed paraffin-embedded tumor tissue. Sci Rep2020; 10: 21292.
48.
ChauhanSSenSSharmaA, et al.P16(INK4a) overexpression as a predictor of survival in ocular surface squamous neoplasia. Br J Ophthalmol2018; 102: 840–847.
49.
ShieldsJAShieldsCLDe PotterP. Surgical management of conjunctival tumors. The 1994 lynn B. McMahan lecture. Arch Ophthalmol1997; 115: 808–815.
50.
NanjiAAMoonCSGalorA, et al.Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. Ophthalmology2014; 121: 994–1000.
51.
LeeGAHirstLW. Retrospective study of ocular surface squamous neoplasia. Aust N Z J Ophthalmol1997; 25: 269–276.
52.
YeohCHYLeeJJRLimBXH, et al.The Management of Ocular Surface Squamous Neoplasia (OSSN). Int J Mol Sci2022; 24: 713.
PolskiASibug SaberMKimJW,et al.Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia. Clin Exp Ophthalmol2019; 47: 193–200.
55.
HӧllhumerRWilliamsSMichelowP. Observational study of ocular surface squamous neoplasia: risk factors, diagnosis, management and outcomes at a tertiary eye hospital in South Africa. PLoS One2020; 15: e0237453.
56.
Al BayyatGArreaza-KaufmanDVenkateswaranN, et al.Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis (Lond)2019; 6: 24.
57.
KalikiSSinghSIramS,et al.Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients. Indian J Ophthalmol2016; 64: 702–709.
58.
SripawadkulWReyes-CapoDZeinM, et al.Long term study of topical interferon α-2b eye drops as primary treatment of ocular surface squamous neoplasia. Ocul Surf2023; 28: 108–114.
59.
KusumeshRAmbasthaASinhaB,et al.Topical interferon α-2b as a single therapy for primary ocular surface squamous neoplasia. Asia Pac J Ophthalmol (Phila)2015; 4: 279–282.
60.
KimHJShieldsCLShahSU, et al.Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction. Ophthalmology2012; 119: 938–944.
61.
ShieldsCLPauloseSAYaghyA, et al.Ocular surface squamous neoplasia managed with primary interferon α2b: a comparative analysis of 212 tumors in smokers versus nonsmokers. Cornea2021; 40: 1387–1394.
62.
SiedleckiANTappSTostesonAN, et al.Surgery versus interferon alpha-2b treatment strategies for ocular surface squamous neoplasia: a literature-based decision analysis. Cornea2016; 35: 613–618.
63.
PatelUKarpCLDubovySR. Update on the management of ocular surface squamous neoplasia. Curr Ophthalmol Rep2021; 9: 7–15.
64.
RudkinAKDempsterLMueckeJS. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy. Clin Exp Ophthalmol2015; 43: 20–25.
65.
JoagMGSiseAMurilloJC, et al.Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology2016; 123: 1442–1448.
66.
AlvarezOPZeinMSerranoA, et al.Punctal and canalicular stenosis following Topical 1% 5-fluorouracil eye drop therapy for ocular surface squamous neoplasia. Cornea2024; 43: 1418–1422.
67.
ShieldsCLNaseripourMShieldsJA. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol2002; 133: 601–606.
GreenfieldJACohenAKGalorA, et al.Ocular surface squamous neoplasia: changes in the standard of care 2003 to 2022. Cornea2024; 43: 942–949.
70.
SturgesAButtALLaiJE,et al.Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia. Ophthalmology2008; 115: 1297– 302.e1.
71.
GichuhiSMachariaEKabiruJ, et al.Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health2016; 4: e378–e385.
72.
GengWWangJSShiBJ, et al.Topical chemotherapy for treating ocular surface squamous neoplasia with a combination of interferon α-2b and 5-fluorouracil. Ophthalmol Ther2022; 11: 1563–1576.
73.
BowenRCSotoHRavalV, et al.Ocular surface squamous neoplasia: outcomes following primary excision with 2 mm margin and cryotherapy. Eye (Lond)2021; 35: 3102–3109.
74.
GalorAKarpCLOellersP, et al.Predictors of ocular surface squamous neoplasia recurrence after excisional surgery. Ophthalmology2012; 119: 1974–1981.
75.
BahramiBGreenwellTMueckeJS. Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia. Clin Exp Ophthalmol2014; 42: 317–322.
76.
XieBChenZLuoJ, et al.Exploring the risk factors of conjunctival squamous cell carcinoma and establishing a prognostic model: retrospective study. Dis Markers2022; 2022: 5427579.
